Research Summary

Next-generation sequencing technologies developed in the last ten years have dramatically widened our view into the many kinds of events that are driving tumor biology. Gene fusions, copy number alterations, mutations, epigenetic changes, stromal microenvironment, immunogenicity and transcript level alterations can all be ascertained via the knife of DNA and RNA sequencing. Statistical methods, factor analysis, insights from evolutionary biology and immunology as well as an understanding of mutation processes at work in tumors can help us distill out the important driver events from the background of non-functional passenger mutations, and give us useful insights into the multiple systemic processes driving tumor progression.

I am specifically interested in using these integrated approaches to help understand and improve treatments for gynecologic cancers. However, the "organ of origin" approach has narrowed our view and exploring carcinogenesis pan-cancer will allow for novel insights into uncommon or difficult to treat gynecologic cancers. To this end, I collaborate with clinicians and scientists across oncology with a goal to further a model of cancer medicine in which genetic data is incorporated.

Education

Carnegie Mellon University, Pittsburgh, PA, B.F.A., 1996-1999, Classical piano
Columbia University, New York, NY, Post-bac, 2002-2003, Pre-medical sciences
Boston University School of Medicine, Boston, MA, M.D., 2004-2008, Medicine
University of California San Francisco, Resident, 2008-2012, Obstetrics, Gynecology & Reproductive Sciences
Stanford University and UCSF, Fellow, 2012-2015, Gynecologic Oncology

Honors & Awards

  • 2009
    Outstanding Resident Award in Medical Student Teaching
  • 2010
    Alpha Omega Alpha
  • 2011
    Resident Scholar - Association of Professors of Gynecology and Obstetrics
  • 2013 & 2014
    Outstanding Fellow Award in Medical Student Teaching
  • 2015
    Leo Lagasse Award for best fellow presentation on clinical research at the 2015 Western Association of Gynecologic Oncologists Annual Meeting

Selected Publications

  1. Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 01 06; 185(1):184-203.e19.  View on PubMed
  2. Korenaga TK, Yoshida EJ, Pierson W, Chang J, Ziogas A, Swanson ML, Chapman JS, Sinha S, Chen LM. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecol Oncol. 2022 02; 164(2):348-356.  View on PubMed
  3. McNamara B, Guerra R, Qin J, Craig AD, Chen LM, Varma MG, Chapman JS. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol Rep. 2021 Nov; 38:100870.  View on PubMed
  4. Craig AD, Garcia E, Peters PN, Chen LM, Chapman JS. Primary treatment of advanced ovarian cancer: how does the 'real world' practice? Future Oncol. 2021 Dec; 17(34):4687-4696.  View on PubMed
  5. Peters PN, Pierson WE, Chen LM, Westphalen AC, Chapman JS, Hsu IC. PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer. Abdom Radiol (NY). 2021 01; 46(1):341-350.  View on PubMed
  6. Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020 04; 157(1):55-61.  View on PubMed
  7. Ahmad TR, Chen LM, Chapman JS, Chen LL. Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology. Gynecol Oncol. 2019 10; 155(1):93-97.  View on PubMed
  8. Ladwig NR, Schoolmeester JK, Weil L, Chapman JS, Zaloudek C, Umetsu SE. Inflammatory Myofibroblastic Tumor Associated With the Placenta: Short Tandem Repeat Genotyping Confirms Uterine Site of Origin. Am J Surg Pathol. 2018 06; 42(6):807-812.  View on PubMed
  9. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM. Disparities in genetics assessment for women with ovarian cancer: Can we do better? Gynecol Oncol. 2018 04; 149(1):84-88.  View on PubMed
  10. Ohliger MA, Hope TA, Chapman JS, Chen LM, Behr SC, Poder L. PET/MR Imaging in Gynecologic Oncology. Magn Reson Imaging Clin N Am. 2017 Aug; 25(3):667-684.  View on PubMed
  11. Chen LM, Chen LL, Chapman JS. In Reply. Obstet Gynecol. 2017 01; 129(1):208.  View on PubMed
  12. Roddy E, Chapman J. Genomic insights in gynecologic cancer. Curr Probl Cancer. 2017 Jan - Feb; 41(1):8-36.  View on PubMed
  13. Chapman JS, Roddy E, Ueda S, Brooks R, Chen LL, Chen LM. Enhanced Recovery Pathways for Improving Outcomes After Minimally Invasive Gynecologic Oncology Surgery. Obstet Gynecol. 2016 07; 128(1):138-144.  View on PubMed
  14. Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS. Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course". J Natl Compr Canc Netw. 2016 Mar; 14(3):lxvi-lxviii.  View on PubMed
  15. Chapman JS, Collisson EA, Taylor BS. The Authors Respond. J Natl Compr Canc Netw. 2016 Mar; 14(3):lxviii.  View on PubMed
  16. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, Schultz N, Taylor BS. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016 Feb; 34(2):155-63.  View on PubMed
  17. Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS. Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. J Natl Compr Canc Netw. 2015 Jul; 13(7):835-45.  View on PubMed
  18. Chapman JS, Roddy E, Westhoff G, Simons E, Brooks R, Ueda S, Chen L. Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decreases wound complications. Gynecol Oncol. 2015 Jun; 137(3):523-8.  View on PubMed
  19. Chapman JS, Jacoby V, Chen LM. Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):40-4.  View on PubMed
  20. Henderson JT, Harper CC, Gutin S, Saraiya M, Chapman J, Sawaya GF. Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists. Am J Obstet Gynecol. 2013 Feb; 208(2):109.e1-7.  View on PubMed

Go to UCSF Profiles, powered by CTSI